LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Regulus Therapeutics Inc

Fermé

7.86 0.26

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.84

Max

7.87

Chiffres clés

By Trading Economics

Revenu

-13M

Ventes

340K

340K

BPA

-0.15

Marge bénéficiaire

-3,762.059

Employés

34

EBITDA

-13M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+12.1% upside

Dividendes

By Dow Jones

Prochains Résultats

6 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

310M

545M

Ouverture précédente

7.6

Clôture précédente

7.86

Regulus Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 avr. 2025, 16:35 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Regulus Shares Surge on $1.7 Billion Acquisition by Novartis

30 avr. 2025, 11:55 UTC

Acquisitions, Fusions, Rachats

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Billion

30 avr. 2025, 11:54 UTC

Acquisitions, Fusions, Rachats

Novartis to Acquire Regulus in $1.7 Billion Deal

30 avr. 2025, 11:40 UTC

Acquisitions, Fusions, Rachats

Novartis to Acquire MicroRNA-Technology Specialist Regulus for Up to $1.7 Bln

30 avr. 2025, 11:39 UTC

Acquisitions, Fusions, Rachats

Novartis to Acquire Regulus in $1.7B Deal

30 avr. 2025, 11:16 UTC

Acquisitions, Fusions, Rachats

Novartis: Transaction Is Expected to Close in Second Half of 2025

30 avr. 2025, 11:15 UTC

Acquisitions, Fusions, Rachats

Novartis: Regulus Therapeutics Is U.S. Biotech Focused on microRNA Therapeutics

30 avr. 2025, 11:14 UTC

Acquisitions, Fusions, Rachats

Novartis: Transaction Includes USD0.8B Upfront Payment, Potential Additional USD 0.9B Payment

30 avr. 2025, 11:13 UTC

Acquisitions, Fusions, Rachats

Novartis to Buy Regulus Therapeutics

Comparaison

Variation de prix

Regulus Therapeutics Inc prévision

Objectif de Prix

By TipRanks

12.1% hausse

Prévisions sur 12 Mois

Moyen 8.8 USD  12.1%

Haut 11 USD

Bas 7 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

6 ratings

1

Achat

5

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Regulus Therapeutics Inc

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.